Seriously WE should be selling this Bio..

I know the WHY's it just kills me that's all.

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis | The Motley Fool

 

This company has no faith in it's sales force. For the most part BI drugs are sold with another company or giving completely away to another sales force for licensing rights. BI will be coming out with a generic for Humara (a 6 BILLION $ drug) but word is that BI sales force will not be touching it.

 

BIPI hires B rate representatives who would crap the BED trying to sell in that market.
They would check their tires when an office asked how to access the hub.
Leave it to the reps who know biotech and SP navigation and can actually articulate Phosphofructokinase. You gotta know how to competitively position this new molecule. BI will provide the commission bucks for the Abbvie Allstars

 

You have no idea what you’re talking about. Where did you hear this “word”that the salesforce will not touch the bio similar? You couldn’t be farther from the truth.

 

Here's the rub I was actively selling biosimilars back in the 90's as a new rep and did it quite successfully. Please get over yourself.

 

Really... biosimilars in the 90s... do tell, what compounds?

 

IV antibiotics; RHU arthritis medication; vaccines, injectable synthetic compounds for joints..BUY AND BILL, got physical order, had to close and all done in my late 20's early 30's.. We were taught and given the challenge and guess what WE DID IT. Again get over yourself.

 

biologic (a product derived from a living organism), provided that it is “highly similar” to the original FDA-approved product.

Note the first biosimilar was marketed in 2005.

Buy and bill is good experience but selling a generic interchange is not the same as selling a biosimilar.

 

And if you don’t believe me just do some research- the launch of biosimilar agents has proven to. be MUCH more difficult than anticipated. Part of it is clinical but the financial business math does not work out that well either.

 

There are great good and bad reps. There are also many highly intelligent teps in this co with the skill set to sell. I personally sold an injectable under a buy and bill and did fantastic. So to make a blanket statement like that is plain stupid.

 

Hello...it's ALL DIFFICULT

 

There is no drug named Humara. It's Humira, and it is a $19 Billion drug.

 

No, you weren't!

 

when we are able to sell Cyltezo, we will probably not need a sales force. The PBM’s will drive use especially if we get good interchange data and policy.

 

Good spell check. There are seven different indications. The one BI will receive is for 6 Billion. The point is that you get 10% of that market just by pricing and you have a hit (by BI standards anyway)